The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
Publications
Acute Eosinophilic Pneumonia Triggered by Carbamazepine Therapy: A Clinical and Radiologic Case Report.
Cureus. 2026;18(5):e108598
Carbamazepine-induced interstitial pneumonitis in a lung transplant patient.
Respiratory medicine. 2006;100(9):1660-2
[Acute eosinophilic pneumonia due to hypersensitivity to carbamazepine].
Revue des maladies respiratoires. 1998;15(6):797-9
Pulmonary eosinophilia and asthma associated with carbamazepine.
British medical journal (Clinical research ed.). 1981;282(6262):440
Pulmonary eosinophilia associated with carbamazepine.
Archives of disease in childhood. 1983;58(10):833-4
[Immuno-allergic side effects induced by the administration of carbamazepine. Case contribution].
Minerva medica. 1984;75(27):1651-5
Carbamazepine and the lung.
The European respiratory journal. 1990;3(8):930-1
Acute pulmonary hypersensitivity to carbamazepine.
Chest. 1975;68(4):580-1
Acute hypersensitivity pneumonitis associated with carbamazepine therapy.
Chest. 1978;74(4):463-4